Future HIV Therapy

Male circumcision is not the HIV ``vaccine'' we have been waiting for!
pp. 193-199(7)
Authors: Green, Lawrence W; McAllister, Ryan G; Peterson, Kent W; Travis, John W

When should antiretroviral therapy be started for HIV-infected infants in resource-limited settings?
pp. 201-208(8)
Authors: Prendergast, Andrew; Cotton, Mark; Gibb, Diana M

US pledges billions to fight AIDS
pp. 209-211(3)

Developing HIV-1 vaccines with a positive attitude
pp. 213-216(4)
Authors: Hanke, Tomáášš

Raltegravir: opening the road for integrase inhibitors in clinical practice
pp. 217-227(11)
Authors: Sued, Omar; Cahn, Pedro

The POWER and TITAN trials: darunavir/ritonavir in the management of HIV-infected patients
pp. 229-245(17)
Author: Katlama, Christine

SOCS1: a host factor required for HIV-1 Gag trafficking
pp. 247-251(5)
Authors: Sivakumaran, Haran; Harrich, David

Carbohydrates on HIV: mediators of immune evasion and targets for antiviral intervention
pp. 253-257(5)
Authors: Pööhlmann, Stefan

Genes and screens: the search for novel chemotherapeutic targets
pp. 259-261(3)
Author: Sheehy, Ann M

Immune restoration disease complicating antiretroviral therapy in patients with HIV infection: implications and solutions
pp. 263-270(8)
Authors: French, Martyn A; Price, Patricia

Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction
pp. 271-280(10)
Authors: Rumbaugh, Jeffrey A; Steiner, Joseph; Sacktor, Ned; Nath, Avindra

Role of miRNA in HIV-1 latency
pp. 281-290(10)
Author: Zhang, Hui

Acknowledgements
pp. 295-295(1)